Phase Ib Trial of the Combination of PI3K Inhibitor BAY80-6946 and Allosteric-MEK Inhibitor BAY86-9766 in Subjects With Advanced Cancer.
Phase of Trial: Phase I
Latest Information Update: 24 Apr 2015
At a glance
- Drugs Copanlisib (Primary) ; Refametinib (Primary)
- Indications Solid tumours
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Bayer
- 02 Sep 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 25 Feb 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 30 Sep 2013 Planned end date changed from 1 Sep 2014 to 1 Jul 2014 as reported by ClinicalTrials.gov.